Estee Lauder (EL) Surpasses Q4 Earnings and Revenue Estimates

Estee Lauder (EL) reported Q4 earnings of $0.09 per share and revenues of $3.41 billion for the quarter ended June 2025, both surpassing Zacks consensus estimates. While EPS declined from $0.64 a year ago and revenues were down from $3.87 billion, the company has consistently beaten estimates and its stock has outperformed the S&P 500 year-to-date, gaining 19.9%. Despite these beats, the stock carries a Zacks Rank #3 (Hold), and its industry remains in the bottom quartile of Zacks-ranked industries, indicating that future stock movement will largely depend on management's commentary.

Analysis

Estee Lauder (EL) reported Q4 results that surpassed consensus estimates, with earnings per share of $0.09 versus an expected $0.08 and revenues of $3.41 billion narrowly beating forecasts. This marks the fourth consecutive quarter the company has exceeded EPS expectations. However, these figures represent a severe year-over-year deterioration, with EPS plunging from $0.64 and revenue falling from $3.87 billion in the same period last year. This fundamental weakness contrasts sharply with the stock's strong market performance, having gained 19.9% year-to-date, more than double the S&P 500's 9% gain. The outlook remains cautious, as reflected by a Zacks Rank #3 (Hold), which suggests the stock is expected to perform in line with the market. Compounding the uncertainty is the poor standing of the broader Cosmetics industry, which ranks in the bottom 24% of over 250 Zacks industries, indicating a significant sector headwind. The sustainability of the stock's recent rally will therefore heavily depend on management's forward-looking commentary to justify the valuation in the face of declining core metrics.

Key Decisions for Investors

• Given the stock's significant 19.9% year-to-date outperformance against a backdrop of sharply declining year-over-year revenue and earnings, investors should consider trimming positions or implementing protective stop-loss orders.
• The upcoming earnings call is critical; scrutinize management's commentary for specific plans to reverse the severe revenue and profit deterioration, as this will be the key catalyst for future performance.
• Remain cautious of the stock's exposure to a poorly performing sector, as the Cosmetics industry's ranking in the bottom quartile suggests potential for broad weakness that could overwhelm company-specific news.
• The disconnect between the strong share price momentum and the weak underlying fundamentals, combined with a neutral 'Hold' rating, suggests waiting for a clearer turnaround story before initiating new long positions.